China’s Shanghai Green Valley Pharmaceuticals has clearance to begin a late stage clinical trial to support a US filing of its potential Alzheimer’s drug.
China’s drugs regulator has conditionally approved Shanghai Green Valley Pharmaceuticals’ Oligomannate to improve cognitive function in mild to moderate Alzheimer’s disease, the first novel
Anyone who has taken a psychiatric medication knows that the status quo in prescribing is a trial and error approach, with patients often cycling through an array of drugs to find the one t
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.